Single-dose prophylactic ibuprofen therapy for patent ductus arteriosus in preterm infants

Area of Science:

• Neonatal Medicine
• Pediatric Cardiology
• Pharmacology

Background:

• Patent ductus arteriosus (PDA) is a common complication in preterm infants.
• Early intervention for PDA is crucial to prevent adverse outcomes.
• Current treatment strategies for PDA have limitations.

Purpose of the Study:

• To evaluate the efficacy and short-term morbidities of single-dose prophylactic intravenous ibuprofen for PDA.
• To assess the impact of early ibuprofen administration on PDA closure and related complications in preterm infants.

Main Methods:

• A cohort study of 69 preterm infants (birth weight < 1250g, gestational age < 30 weeks) was conducted.
• Infants were divided into a prophylactic treatment (PT) group (n=37) receiving ibuprofen within 6 hours of birth and a non-PT group (n=32).
• Outcomes measured included PDA closure rates, need for later PDA treatment, intraventricular hemorrhage (IVH), duration of ventilatory support, and central venous catheter use.

Main Results:

• PDA closure by day 7 occurred in 94.6% of the PT group versus 34.4% in the non-PT group.
• The PT group showed significantly lower rates of moderate-to-large PDA requiring treatment after day 7 (5.4% vs 28.1%).
• Prophylactic ibuprofen reduced the incidence of severe intraventricular hemorrhage (≥grade 2), shortened invasive ventilatory support, central venous catheter duration, and hospital stay.

Conclusions:

• Single-dose prophylactic intravenous ibuprofen on the first day of life is effective in achieving PDA closure in high-risk preterm infants.
• This prophylactic approach significantly reduces the incidence of severe intraventricular hemorrhage and other short-term morbidities.
• Early administration of ibuprofen offers benefits including shorter ventilation duration, reduced central venous catheter use, and potentially shorter hospital stays.